4-Morpholinecarboxylicacid,2-[[(7-chloropyrido[3,4-b]pyrazin-5-yl)amino]methyl]-,1,1-dimethylethylester

4-Morpholinecarboxylicacid,2-[[(7-chloropyrido[3,4-b]pyrazin-5-yl)amino]methyl]-,1,1-dimethylethylester Suppliers list
Company Name: Shanghai Balmxy Pharmaceutical Co., Ltd  
Tel: 021-24206007 13764915196
Email: sales@balmxy.com
Company Name: Amadis Chemical Company Limited  
Tel: 571-89925085
Email: sales@amadischem.com
Company Name: Kaixin Chemical (Hong Kong) Limited  
Tel: 010-88886666-01 13112345678
Email: loyson@qq.com
Company Name: Birdo (Shanghai) Medical Technology Co., Ltd.  
Tel: 021-58099077-8041 18601625411
Email: sales@birdotech.com
Company Name: Taizhou Nanfeng Pharmaceutical Research Institute  
Tel: nanfengpharma@126.co 18616377689
Email: nanfengpharma@126.com
4-Morpholinecarboxylicacid,2-[[(7-chloropyrido[3,4-b]pyrazin-5-yl)amino]methyl]-,1,1-dimethylethylester Basic information
Product Name:4-Morpholinecarboxylicacid,2-[[(7-chloropyrido[3,4-b]pyrazin-5-yl)amino]methyl]-,1,1-dimethylethylester
Synonyms:(R)-tert-Butyl 2-((7-chloropyrido[4,3-b]pyrazin-5-ylamino)methyl)morpholine-4-carboxylate;4-Morpholinecarboxylicacid,2-[[(7-chloropyrido[3,4-b]pyrazin-5-yl)amino]methyl]-,1,1-dimethylethylester;tert-butyl (R)-2-(((7-chloropyrido[3,4-b]pyrazin-5-yl)amino)methyl)morpholine-4-carboxylate;4-Morpholinecarboxylic acid, 2-[[(7-chloropyrido[3,4-b]pyrazin-5-yl)amino]methyl]-, 1,1-dimethylethyl ester, (2R)-;AM19040S1
CAS:1400589-53-8
MF:C17H22ClN5O3
MW:379.84
EINECS:
Product Categories:
Mol File:1400589-53-8.mol
4-Morpholinecarboxylicacid,2-[[(7-chloropyrido[3,4-b]pyrazin-5-yl)amino]methyl]-,1,1-dimethylethylester Structure
4-Morpholinecarboxylicacid,2-[[(7-chloropyrido[3,4-b]pyrazin-5-yl)amino]methyl]-,1,1-dimethylethylester Chemical Properties
Boiling point 552.879±50.00 °C(Press: 760.00 Torr)(predicted)
density 1.326±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted)
storage temp. under inert gas (nitrogen or Argon) at 2–8 °C
pka3.430±0.30(predicted)
Safety Information
MSDS Information
4-Morpholinecarboxylicacid,2-[[(7-chloropyrido[3,4-b]pyrazin-5-yl)amino]methyl]-,1,1-dimethylethylester Usage And Synthesis
Synthesis
(R)-2-Aminomethyl-4-boc-morpholine

1174913-80-4

5,7-Dichloropyrido[4,3-b]pyrazine

1379338-74-5

4-Morpholinecarboxylicacid,2-[[(7-chloropyrido[3,4-b]pyrazin-5-yl)amino]methyl]-,1,1-dimethylethylester

1400589-53-8

The general procedure for the synthesis of tert-butyl (R)-2-((7-chloropyrido[4,3-b]pyrazin-5-ylamino)methyl)morpholine-4-carboxylate from (R)-2-(aminomethyl)morpholine-4-carboxylic acid tert-butyl ester and 5,7-dichloro pyrido[3,4-b]pyrazine was as follows: Intermediate 22: 1,1-dimethylethyl (2R)-2-{[(7-chloropyrido[3,4-b]pyrazin-5-yl)amino]methyl}-4-morpholinecarboxylate 1. tert-Butyl (R)-2-(aminomethyl)morpholine-4-carboxylate (6 g, 27.7 mmol) was dissolved in N-methyl-2-pyrrolidone (NMP). 2. N,N-diisopropylethylamine (DIPEA, 7.27 mL, 41.6 mmol) and 5,7-dichloropyrido[3,4-b]pyrazine (5.55 g, 27.7 mmol) were added to the above solution. 3. The reaction mixture was homogenized into four large microwave reaction flasks and each flask was heated at 130 °C for 30 min. 4. The progress of the reaction was monitored by liquid chromatography-mass spectrometry (LCMS), and the reaction was continued at 130 °C for 10 min if necessary. 5. Upon completion of the reaction, the reaction mixture was partitioned between ethyl acetate (700 mL) and dilute aqueous ammonium chloride solution (1 L). 6. The aqueous layer was re-extracted with ethyl acetate (300 mL) and the organic phases were combined. 7. The combined organic phases were washed with aqueous ammonium chloride (500mL), dried over anhydrous sodium sulfate and concentrated in vacuum to give the crude product as a brown oil. 8. The crude product was dissolved in dichloromethane (DCM) and purified by silica gel column (70g). 9. Eluted sequentially with the following eluents: pure DCM (6 x 40mL), 5% ethyl acetate in DCM (2 x 40mL), 10% ethyl acetate in DCM (5 x 40mL), 15% ethyl acetate in DCM (appropriate amount), 20% ethyl acetate in DCM (2 x 40mL). 10. The suitable elution grades were collected, combined and concentrated in vacuum to give the target product N8231-100-2 as an orange-yellow, slightly gelatinous solid in a yield of 7.7 g. The product was then concentrated in vacuo. 11. LCMS (Method B) analysis: retention time (Rt) = 1.17 min, molecular ion peak (MH+) = 380.

References[1] Patent: WO2012/123312, 2012, A1. Location in patent: Page/Page column 73-74
[2] Patent: US2014/5188, 2014, A1. Location in patent: Paragraph 0621; 0622; 0623
4-Morpholinecarboxylicacid,2-[[(7-chloropyrido[3,4-b]pyrazin-5-yl)amino]methyl]-,1,1-dimethylethylester Preparation Products And Raw materials
Raw materials5,7-Dichloropyrido[4,3-b]pyrazine-->(R)-2-Aminomethyl-4-boc-morpholine-->2,6-Dichloropyridine-3,4-diamine-->N,N-Diisopropylethylamine-->N-Methyl-2-pyrrolidone
Tag:4-Morpholinecarboxylicacid,2-[[(7-chloropyrido[3,4-b]pyrazin-5-yl)amino]methyl]-,1,1-dimethylethylester(1400589-53-8) Related Product Information
Nifedipine 3-[(3-Chloro-quinoxalin-2-ylaMino)-Methyl]-piperidine-1-carboxylic acid tert-butyl ester, 98+% C19H25ClN4O2, MW: 376.88 4-[(3-Chloro-quinoxalin-2-ylaMino)-Methyl]-piperidine-1-carboxylic acid tert-butyl ester, 98+% C19H25ClN4O2, MW: 376.88 4-(3-Chloro-quinoxalin-2-ylaMino)-piperidine-1-carboxylic acid tert-butyl ester, 98+% C18H23ClN4O2, MW: 362.86 tert-Butyl 4-(2,7-dichloropyrido[4,3-d]pyrimidin-4-yl)piperazine-1-carboxylate 3-(3-Chloro-quinoxalin-2-ylaMino)-piperidine-1-carboxylic acid tert-butyl ester, 98+% C18H23ClN4O2, MW: 362.86